Literature DB >> 7791798

Cyclin E restores p53 activity in contact-inhibited cells.

A Deffie1, M Hao, R Montes de Oca Luna, D L Hulboy, G Lozano.   

Abstract

The wild-type p53 protein is a potent growth suppressor when overexpressed in vitro. It functions as a transcriptional activator and causes growth arrest at the G1/S stage of the cell cycle. We monitored p53 transactivation as an indicator of p53 function throughout the cell cycle. We first demonstrate that cells which exhibited contact inhibition of growth lacked p53 transactivation function at high cell density. Since these cells were noncycling, we examined whether the ectopic expression of any cyclin could override contact inhibition of growth and restore p53 transactivation function. The transfection of cyclin E at high cell density stimulated the progression of cells through the cell cycle and restored p53 transactivation function. The transcriptional activity of p53 induced by cyclin E was regulated at the level of DNA binding. Cells that did not show contact inhibition of growth had a functional p53 regardless of cell density. Thus, contact inhibition of cell growth corresponded to a lack of p53 transactivation function and the overexpression of cyclin E in these contact-inhibited cells stimulated cell cycle progression and resulted in p53 transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791798      PMCID: PMC230632          DOI: 10.1128/MCB.15.7.3926

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

3.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration.

Authors:  J L Sherley
Journal:  J Biol Chem       Date:  1991-12-25       Impact factor: 5.157

6.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

Authors:  J Martinez; I Georgoff; J Martinez; A J Levine
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

7.  Oncogenic forms of p53 inhibit p53-regulated gene expression.

Authors:  S E Kern; J A Pietenpol; S Thiagalingam; A Seymour; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

8.  Wild-type p53 activates transcription in vitro.

Authors:  G Farmer; J Bargonetti; H Zhu; P Friedman; R Prywes; C Prives
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

9.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

10.  A potential transcriptional activation element in the p53 protein.

Authors:  R W O'Rourke; C W Miller; G J Kato; K J Simon; D L Chen; C V Dang; H P Koeffler
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

View more
  6 in total

Review 1.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.

Authors:  Michaela Beitzinger; Lars Hofmann; Claudia Oswald; Rasa Beinoraviciute-Kellner; Markus Sauer; Heidi Griesmann; Anne Catherine Bretz; Christof Burek; Andreas Rosenwald; Thorsten Stiewe
Journal:  EMBO J       Date:  2008-01-31       Impact factor: 11.598

3.  Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

Authors:  Luis Alfonso Martinez; Irina Naguibneva; Heike Lehrmann; Arlette Vervisch; Thierry Tchénio; Guillermina Lozano; Annick Harel-Bellan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-28       Impact factor: 11.205

Review 4.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells.

Authors:  M O Trielli; P R Andreassen; F B Lacroix; R L Margolis
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

6.  A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells.

Authors:  Lorenzo Messa; Marta Celegato; Chiara Bertagnin; Beatrice Mercorelli; Giulio Nannetti; Giorgio Palù; Arianna Loregian
Journal:  Sci Rep       Date:  2018-04-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.